EGFR and non-small cell lung carcinoma: Gefitinib is a first generation EGFR-TKI that was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) in 2002 as a monotherapy treatment for inoperable or recurrent NSCLC.